Construction of Optimized Bispecific Antibodies for Selective Activation of the Death Receptor CD95
Authors:
Open Access
- 15 February 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 68 (4) , 1221-1227
Abstract
We have previously reported that bispecific antibodies directed to different target antigens on lymphoma cells and to the death receptor CD95/Fas/Apo-1 selectively kill these cells, thus providing an attractive strategy for the selective stimulation of CD95 on the surface of tumor cells. Here, we further explore the general applicability of this approach under more stringent conditions using various bispecific antibodies directed to different target antigens on glioblastoma cells which express relatively low levels of CD95. We found that bispecific CD95 antibodies targeting the neuronal glial antigen-2 induce CD95-mediated apoptosis selectively in glioblastoma cells expressing this target antigen. A recombinant bispecific single-chain antibody was as effective as a chemically hybridized F(ab′)2 fragment with identical specificities. In contrast, a bispecific F(ab′)2 fragment binding to the epidermal growth factor receptor on the glioblastoma cells failed to induce apoptosis. This is most likely due to the exclusively unicellular binding of this particular fragment to target cells expressing both the epidermal growth factor receptor and CD95. If this type of binding in a cis configuration is favored by a particular bispecific antibody, rather than a bicellular binding in trans, effective cross-linking of CD95 does not occur and apoptosis is not induced. To facilitate bicellular binding in a trans configuration, we constructed a bispecific antibody directed to the extracellular matrix protein tenascin. As expected, this reagent was the most effective of all the antibodies tested. The presence of sensitizing reagents such as cycloheximide and various cytostatic drugs further enhanced antibody-mediated killing of the tumor cells. We believe that these results may point the way to a successful application of bispecific CD95 antibodies in experimental tumor therapy. [Cancer Res 2008;68(4):1221–7]Keywords
This publication has 23 references indexed in Scilit:
- Intracellular Triggering of Fas Aggregation and Recruitment of Apoptotic Molecules into Fas-enriched Rafts in Selective Tumor Cell ApoptosisJournal of Experimental Medicine, 2004
- Generation of a FasL-based Proapoptotic Fusion Protein Devoid of Systemic Toxicity due to Cell-surface Antigen-restricted ActivationJournal of Biological Chemistry, 2003
- Tenascins: regulation and putative functions during pathological stressThe Journal of Pathology, 2003
- A recombinant bispecific single‐chain antibody induces targeted, supra‐agonistic CD28‐stimulation and tumor cell killingEuropean Journal of Immunology, 2003
- Phase II Trial of Murine 131I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant GliomasJournal of Clinical Oncology, 2002
- Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transferOncogene, 2001
- Colchicine protects mice from the lethal effect of an agonistic anti-Fas antibodyJournal of Clinical Investigation, 2000
- Lethal effect of the anti-Fas antibody in miceNature, 1993
- Monoclonal Antibody-Mediated Tumor Regression by Induction of ApoptosisScience, 1989
- A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor.Journal of Experimental Medicine, 1989